Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System - Gastaldon, C; Raschi, E; Kane, JM (Psychother Psychosom, 2021)
et al.